Despite promising results in some subtypes of lymphoma, currently being approved in HL and PMCBL, PD-1/PD-L1 checkpoint inhibitors have shown disappointing results in trials investigating their use as single agent, in both, de novo and relapsed AML. This evidence concerns the gene CD274 and lymphoma.